Metastatic castration-resistant prostate cancer is a form of prostate cancer that has spread beyond the prostate and continues to grow even when testosterone levels are low. The study evaluates two treatment approaches: an intravenous medication called BNT324 and a chemotherapy drug called docetaxel given together with oral prednisone.
The purpose of the study is to compare how well BNT324 works against docetaxel in slowing disease progression and extending survival. Participants are randomly assigned to one of the two groups and receive the assigned medication in cycles, typically every three weeks, with treatment continuing until the disease worsens, side effects become too severe, or the planned treatment period ends.
During the trial, patients undergo regular imaging scans to check for changes in tumor size, blood tests to monitor prostate‑specific antigen levels, and assessments of pain and overall health. The study records how long the cancer remains stable, the time until death from any cause, and any side effects experienced.
Belgium 
France 
